Advertisement

Bone as an Endocrine Organ: Diabetic Bone Disease as a Cause of Endocrine Disorder via Osteocalcin, FGF23 Secreted from Osteocyte/Osteoblast

  • Koichiro YodaEmail author
Chapter

Abstract

Endocrine effects occur when organs secrete humoral physiologically active substances into the blood or other bodily fluids, and these active substances exert their physiological activities in target tissues. Fibroblast growth factor (FGF) 23, which is secreted by osteocytes, acts on the renal tubule and is involved in phosphorus metabolism. Osteocalcin, which is secreted by osteoblasts, acts on pancreatic β-cells and adipocytes and plays a role in insulin secretion and glycometabolism, in addition to its conventional role as a bone matrix protein. Thus, FGF23 and osteocalcin secreted from bone tissues function as endocrine hormones. Osteocyte and osteoblast functions are decreased in diabetes. Consequently, the secretion of FGF23 and osteocalcin is hindered. The decreased function of FGF23 causes hyperphosphatemia and leads to the progression of arteriosclerosis. The decreased function of osteocalcin results in decreased insulin secretion and increased insulin resistance. In this article, we describe the role of bone as an endocrine organ and its association with diabetes.

Keywords

Undercarboxylated osteocalcin (ucOC) Fibroblast growth factor 23 (FGF23) Diabetes Atherosclerosis Hyperphosphatemia 

References

  1. 1.
    Mirams M, Robinson BG, Mason RS, Nelson AE (2004) Bone as a source of FGF23: regulation by phosphate? Bone 35(5):1192–1199. doi: 10.1016/j.bone.2004.06.014 CrossRefPubMedGoogle Scholar
  2. 2.
    Liu S, Zhou J, Tang W, Jiang X, Rowe DW, Quarles LD (2006) Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab 291(1):E38–E49. doi: 10.1152/ajpendo.00008.2006 CrossRefPubMedGoogle Scholar
  3. 3.
    Terada M, Inaba M, Yano Y, Hasuma T, Nishizawa Y, Morii H, Otani S (1998) Growth-inhibitory effect of a high glucose concentration on osteoblast-like cells. Bone 22(1):17–23CrossRefPubMedGoogle Scholar
  4. 4.
    Alikhani M, Alikhani Z, Boyd C, MacLellan CM, Raptis M, Liu R, Pischon N, Trackman PC, Gerstenfeld L, Graves DT (2007) Advanced glycation end products stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathways. Bone 40(2):345–353. doi: 10.1016/j.bone.2006.09.011 CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Aguiari P, Leo S, Zavan B, Vindigni V, Rimessi A, Bianchi K, Franzin C, Cortivo R, Rossato M, Vettor R, Abatangelo G, Pozzan T, Pinton P, Rizzuto R (2008) High glucose induces adipogenic differentiation of muscle-derived stem cells. Proc Natl Acad Sci U S A 105(4):1226–1231. doi: 10.1073/pnas.0711402105 CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Malladi P, Xu Y, Chiou M, Giaccia AJ, Longaker MT (2006) Effect of reduced oxygen tension on chondrogenesis and osteogenesis in adipose-derived mesenchymal cells. Am J Physiol Cell Physiol 290(4):C1139–C1146. doi: 10.1152/ajpcell.00415.2005 CrossRefPubMedGoogle Scholar
  7. 7.
    Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S, Yamashita T (2006) Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444(7120):770–774. doi: 10.1038/nature05315 CrossRefPubMedGoogle Scholar
  8. 8.
    Cheng MF, Chen LJ, Wang MC, Hsu CT, Cheng JT (2014) Decrease of FGF receptor (FGFR) and interstitial fibrosis in the kidney of streptozotocin-induced diabetic rats. Horm Metab Res 46(1):1–7. doi: 10.1055/s-0033-1349090 PubMedGoogle Scholar
  9. 9.
    Quarles LD (2012) Role of FGF23 in vitamin D and phosphate metabolism: implications in chronic kidney disease. Exp Cell Res 318(9):1040–1048. doi: 10.1016/j.yexcr.2012.02.027 CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Yoda K, Imanishi Y, Yoda M, Mishima T, Ichii M, Yamada S, Mori K, Emoto M, Inaba M (2012) Impaired response of FGF-23 to oral phosphate in patients with type 2 diabetes: a possible mechanism of atherosclerosis. J Clin Endocrinol Metab 97(11):E2036–E2043. doi: 10.1210/jc.2012-2024 CrossRefPubMedGoogle Scholar
  11. 11.
    Muras K, Masajtis-Zagajewska A, Nowicki M (2013) Diabetes modifies effect of high-phosphate diet on fibroblast growth factor-23 in chronic kidney disease. J Clin Endocrinol Metab 98(12):E1901–E1908. doi: 10.1210/jc.2013-2418 CrossRefPubMedGoogle Scholar
  12. 12.
    Isakova T, Wahl P, Vargas GS, Gutierrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend RR, Anderson CA, Lash JP, Hsu CY, Leonard MB, Wolf M (2011) Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79(12):1370–1378. doi: 10.1038/ki.2011.47 CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Agarwal R, Duffin KL, Laska DA, Voelker JR, Breyer MD, Mitchell PG (2014) A prospective study of multiple protein biomarkers to predict progression in diabetic chronic kidney disease. Nephrol Dial Transplant 29(12):2293–2302. doi: 10.1093/ndt/gfu255 CrossRefPubMedGoogle Scholar
  14. 14.
    Hashimoto H, Iijima K, Hashimoto M, Son BK, Ota H, Ogawa S, Eto M, Akishita M, Ouchi Y (2009) Validity and usefulness of aortic arch calcification in chest X-ray. J Atheroscler Thromb 16(3):256–264CrossRefPubMedGoogle Scholar
  15. 15.
    Ishimura E, Okuno S, Kitatani K, Kim M, Shoji T, Nakatani T, Inaba M, Nishizawa Y (2002) Different risk factors for peripheral vascular calcification between diabetic and non-diabetic haemodialysis patients – importance of glycaemic control. Diabetologia 45(10):1446–1448. doi: 10.1007/s00125-002-0920-8 CrossRefPubMedGoogle Scholar
  16. 16.
    Chen NX, Moe SM (2003) Arterial calcification in diabetes. Curr Diabetes Rep 3(1):28–32CrossRefGoogle Scholar
  17. 17.
    Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, Chonchol M, Investigators H (2011) FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol: JASN 22(10):1913–1922. doi: 10.1681/ASN.2010121224 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Juppner H, Wolf M (2008) Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359(6):584–592. doi: 10.1056/NEJMoa0706130 CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Lim K, Lu TS, Molostvov G, Lee C, Lam FT, Zehnder D, Hsiao LL (2012) Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23. Circulation 125(18):2243–2255. doi: 10.1161/CIRCULATIONAHA.111.053405 CrossRefPubMedGoogle Scholar
  20. 20.
    Inaba M, Okuno S, Imanishi Y, Yamada S, Shioi A, Yamakawa T, Ishimura E, Nishizawa Y (2006) Role of fibroblast growth factor-23 in peripheral vascular calcification in non-diabetic and diabetic hemodialysis patients. Osteoporos Int 17(10):1506–1513. doi: 10.1007/s00198-006-0154-6 CrossRefPubMedGoogle Scholar
  21. 21.
    Tamei N, Ogawa T, Ishida H, Ando Y, Nitta K (2011) Serum fibroblast growth factor-23 levels and progression of aortic arch calcification in non-diabetic patients on chronic hemodialysis. J Atheroscler Thromb 18(3):217–223CrossRefPubMedGoogle Scholar
  22. 22.
    Fulzele K, Riddle RC, DiGirolamo DJ, Cao X, Wan C, Chen D, Faugere MC, Aja S, Hussain MA, Bruning JC, Clemens TL (2010) Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition. Cell 142(2):309–319. doi: 10.1016/j.cell.2010.06.002 CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Ferron M, Wei J, Yoshizawa T, Del Fattore A, DePinho RA, Teti A, Ducy P, Karsenty G (2010) Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell 142(2):296–308. doi: 10.1016/j.cell.2010.06.003 CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Engelke JA, Hale JE, Suttie JW, Price PA (1991) Vitamin K-dependent carboxylase: utilization of decarboxylated bone Gla protein and matrix Gla protein as substrates. Biochim Biophys Acta 1078(1):31–34CrossRefPubMedGoogle Scholar
  25. 25.
    Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, Dacquin R, Mee PJ, McKee MD, Jung DY, Zhang Z, Kim JK, Mauvais-Jarvis F, Ducy P, Karsenty G (2007) Endocrine regulation of energy metabolism by the skeleton. Cell 130(3):456–469. doi: 10.1016/j.cell.2007.05.047 CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Kanazawa I, Yamaguchi T, Yamauchi M, Yamamoto M, Kurioka S, Yano S, Sugimoto T (2011) Serum undercarboxylated osteocalcin was inversely associated with plasma glucose level and fat mass in type 2 diabetes mellitus. Osteoporos Int 22(1):187–194. doi: 10.1007/s00198-010-1184-7 CrossRefPubMedGoogle Scholar
  27. 27.
    Yeap BB, Alfonso H, Chubb SA, Gauci R, Byrnes E, Beilby JP, Ebeling PR, Handelsman DJ, Allan CA, Grossmann M, Norman PE, Flicker L (2015) Higher serum undercarboxylated osteocalcin and other bone turnover markers are associated with reduced diabetes risk and lower estradiol concentrations in older men. J Clin Endocrinol Metab 100(1):63–71. doi: 10.1210/jc.2014-3019 CrossRefPubMedGoogle Scholar
  28. 28.
    Okuno S, Ishimura E, Tsuboniwa N, Norimine K, Yamakawa K, Yamakawa T, Shoji S, Mori K, Nishizawa Y, Inaba M (2013) Significant inverse relationship between serum undercarboxylated osteocalcin and glycemic control in maintenance hemodialysis patients. Osteoporos Int 24(2):605–612. doi: 10.1007/s00198-012-2003-0 CrossRefPubMedGoogle Scholar
  29. 29.
    Bullo M, Moreno-Navarrete JM, Fernandez-Real JM, Salas-Salvado J (2012) Total and undercarboxylated osteocalcin predict changes in insulin sensitivity and beta cell function in elderly men at high cardiovascular risk. Am J Clin Nutr 95(1):249–255. doi: 10.3945/ajcn.111.016642 CrossRefPubMedGoogle Scholar
  30. 30.
    Levinger I, Jerums G, Stepto NK, Parker L, Serpiello FR, McConell GK, Anderson M, Hare DL, Byrnes E, Ebeling PR, Seeman E (2014) The effect of acute exercise on undercarboxylated osteocalcin and insulin sensitivity in obese men. J Bone Mineral Res 29(12):2571–2576. doi: 10.1002/jbmr.2285 CrossRefGoogle Scholar

Copyright information

© Springer Japan 2016

Authors and Affiliations

  1. 1.Department of Metabolism, Endocrinology and Molecular MedicineOsaka City University Graduate School of MedicineOsakaJapan

Personalised recommendations